Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGTNASDAQ:RDNTNASDAQ:VCYTNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$20.99-3.4%$19.52$14.57▼$25.11$639.02M1.06285,299 shs145,999 shsRDNTRadNet$56.58-2.2%$54.84$45.00▼$93.65$4.25B1.43689,020 shs458,784 shsVCYTVeracyte$26.69-4.4%$29.55$19.73▼$47.32$2.09B2.09911,440 shs774,320 shsVRDNViridian Therapeutics$15.67-2.6%$13.31$9.90▼$27.20$1.28B0.411.18 million shs1.07 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics-3.36%+0.82%+3.45%+21.75%+5.64%RDNTRadNet-2.23%-2.57%-6.53%+21.57%-8.37%VCYTVeracyte-4.44%-1.07%-8.94%-15.30%+20.93%VRDNViridian Therapeutics-2.61%+10.04%+22.33%-1.57%+23.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics4.0129 of 5 stars2.34.00.04.12.43.30.6RDNTRadNet3.5911 of 5 stars2.72.00.04.62.42.50.0VCYTVeracyte4.0099 of 5 stars4.41.00.04.32.30.00.6VRDNViridian Therapeutics1.8399 of 5 stars4.50.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.50Moderate Buy$24.0014.34% UpsideRDNTRadNet 3.40Buy$69.7523.28% UpsideVCYTVeracyte 2.70Moderate Buy$40.9053.24% UpsideVRDNViridian Therapeutics 2.90Moderate Buy$37.56139.67% UpsideCurrent Analyst Ratings BreakdownLatest VCYT, RDNT, VRDN, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $27.005/7/2025VRDNViridian TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.005/7/2025VRDNViridian TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.005/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $36.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.004/23/2025VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $34.004/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$292.45M2.19$4.10 per share5.12$38.24 per share0.55RDNTRadNet$1.87B2.27$3.01 per share18.81$11.79 per share4.80VCYTVeracyte$463.39M4.51$0.06 per share442.29$14.30 per share1.87VRDNViridian Therapeutics$302K4,233.60N/AN/A$4.48 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%8/1/2025 (Estimated)RDNTRadNet$3.04M-$0.43N/A106.75N/A-0.25%4.29%1.45%8/6/2025 (Estimated)VCYTVeracyte-$74.40M$0.41N/A37.07N/A-2.18%3.02%2.80%8/5/2025 (Estimated)VRDNViridian Therapeutics-$237.73M-$3.85N/AN/AN/A-85,127.16%-70.12%-41.49%8/14/2025 (Estimated)Latest VCYT, RDNT, VRDN, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025VRDNViridian Therapeutics-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A4.414.41RDNTRadNet0.892.162.16VCYTVeracyteN/A5.084.79VRDNViridian Therapeutics0.0418.5518.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%RDNTRadNet77.90%VCYTVeracyteN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics31.76%RDNTRadNet5.60%VCYTVeracyte1.40%VRDNViridian Therapeutics1.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,01030.44 million20.87 millionOptionableRDNTRadNet8,97075.03 million70.24 millionOptionableVCYTVeracyte79078.32 million76.49 millionOptionableVRDNViridian Therapeutics5081.59 million78.70 millionOptionableVCYT, RDNT, VRDN, and FLGT HeadlinesRecent News About These CompaniesViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 12 at 5:49 AM | marketbeat.comViridian Therapeutics: The Song Remains The SameJune 9, 2025 | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)June 7, 2025 | marketbeat.comViridian Therapeutics to Participate in Upcoming June Investor ConferencesMay 30, 2025 | businesswire.comBank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 30, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLCMay 28, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLCMay 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 109,231 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 27, 2025 | marketbeat.comTwo Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 27, 2025 | marketbeat.comVeligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye diseaseMay 22, 2025 | healio.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Sells 209,818 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 22, 2025 | marketbeat.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21, 2025 | investing.comSoleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 21, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Rafferty Asset Management LLCMay 21, 2025 | marketbeat.comViridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye diseaseMay 20, 2025 | ophthalmologytimes.comTang Capital Management LLC Raises Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 20, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 20, 2025 | marketbeat.comDeutsche Bank AG Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 20, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $8.47 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 18, 2025 | marketbeat.comNorthern Trust Corp Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 271,156 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCYT, RDNT, VRDN, and FLGT Company DescriptionsFulgent Genetics NASDAQ:FLGT$20.99 -0.73 (-3.36%) As of 06/12/2025 04:00 PM EasternFulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.RadNet NASDAQ:RDNT$56.58 -1.29 (-2.23%) As of 06/12/2025 04:00 PM EasternRadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$26.69 -1.24 (-4.44%) As of 06/12/2025 04:00 PM EasternVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Viridian Therapeutics NASDAQ:VRDN$15.67 -0.42 (-2.61%) As of 06/12/2025 04:00 PM EasternViridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
